Patients with previously treated metastatic pancreatic cancer are receiving an investigational drug that has not yet been approved, through a federal pathway that opened this spring.
The drug is daraxonrasib, an oral RAS inhibitor developed by Revolution Medicines. In the Phase 3 RASolute 302 trial, patients receiving it had a median overall survival of 13.2 months in the overall study population, compared with 6.7 months for those receiving standard chemotherapy, a 60 percent reduction in the risk of death.
